Recruiting PHASE2 INTERVENTIONAL 4-arm NCT06987643

A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke (RESTORE)

A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke

Sponsor: CervoMed, Inc

Conditions Ischaemic Stroke Moderate to Severe Acute Ischaemic Stroke

Interventions Neflamapimod Placebo

Updated 4 times since 2025 Last updated: Feb 5, 2026 Started: Jun 20, 2025 Primary completion: May 31, 2026 Completion: Jun 28, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ischaemic Stroke and Moderate to Severe Acute Ischaemic Stroke, this trial is actively recruiting participants. The trial is conducted by CervoMed, Inc and has accumulated 4 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2
Oct 2025 — Feb 2026 [monthly]

Recruiting PHASE2
Aug 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Jun 2025 — Aug 2025 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CervoMed, Inc
EIP Pharma Inc

Data source: EIP Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birtinya, Australia , Box Hill, Australia , Brisbane, Australia , Campbelltown, Australia , Clayton, Australia , Fitzroy, Australia , Heidelberg, Australia , Liverpool, Australia , Melbourne, Australia , Southport, Australia and 1 more location